| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.35B | 18.28 | 22.57 | 65.15% | 42.87% | 48.57% | 2.53% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 86.21M | 2.90 | -0.23 | -49.37% | 0.24 | |||
| INOInovio Pharmaceuticals, Inc. | 112.67M | 1.64 | -0.42 | -73.83% | -592.82% | -115.42% | 0.17 | |
| ALGSAligos Therapeutics, Inc. | 48.45M | 9.05 | -0.43 | -74.6% | -32.68% | -120.37% | ||
| BRNSBarinthus Biotherapeutics plc | 30.83M | 0.76 | -0.49 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.99M | 1.16 | -0.67 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 172.81M | 9.24 | -0.79 | -170.84% |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 6.85M | 4.82M | 268K | 44.7M | 802K | 14.97M |
| Revenue Growth % | - | -0.3% | -0.94% | 165.8% | -0.98% | 17.66% |
| Cost of Goods Sold | 29.84M | 14.39M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 4.36% | 2.98% | - | - | - | - |
| Gross Profit | -23M | -9.57M | 268K | 44.7M | 802K | 14.97M |
| Gross Margin % | -3.36% | -1.98% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 0.58% | 1.03% | 165.8% | -0.98% | 17.66% |
| Operating Expenses | 2.67M | 10.48M | 45.49M | 48.74M | 84.72M | 82.94M |
| OpEx % of Revenue | 0.39% | 2.17% | 169.74% | 1.09% | 105.63% | 5.54% |
| Selling, General & Admin | 2.67M | 10.48M | 25.12M | 6.39M | 39.84M | 29.67M |
| SG&A % of Revenue | 0.39% | 2.17% | 93.72% | 0.14% | 49.68% | 1.98% |
| Research & Development | 29.84M | 14.39M | 16.37M | 41.11M | 41.41M | 38.25M |
| R&D % of Revenue | 4.36% | 2.98% | 61.08% | 0.92% | 51.64% | 2.56% |
| Other Operating Expenses | -29.84M | -14.39M | 4M | 1.24M | 3.46M | 15.02M |
| Operating Income | -25.66M | -20.05M | -45.22M | -4.04M | -83.91M | -67.97M |
| Operating Margin % | -3.75% | -4.16% | -168.74% | -0.09% | -104.63% | -4.54% |
| Operating Income Growth % | - | 0.22% | -1.26% | 0.91% | -19.77% | 0.19% |
| EBITDA | -25.5M | -19.84M | -44.62M | 282K | -78.48M | -62.17M |
| EBITDA Margin % | -3.72% | -4.11% | -166.49% | 0.01% | -97.86% | -4.15% |
| EBITDA Growth % | - | 0.22% | -1.25% | 1.01% | -279.32% | 0.21% |
| D&A (Non-Cash Add-back) | 167.62K | 208K | 602K | 4.32M | 5.43M | 5.8M |
| EBIT | -22.69M | -16.77M | -48.47M | 869K | -76.49M | -61.17M |
| Net Interest Income | -92.93K | -3.6M | -2.67M | 3.08M | 2.85M | 2.63M |
| Interest Income | 40.37K | 0 | 2K | 3.1M | 2.88M | 2.68M |
| Interest Expense | 133.3K | 3.6M | 2.67M | 19K | 28K | 53K |
| Other Income/Expense | 2.97M | 2.21M | -5.92M | 4.89M | 7.39M | 6.74M |
| Pretax Income | -22.7M | -17.84M | -51.14M | 850K | -76.52M | -61.23M |
| Pretax Margin % | -3.32% | -3.7% | -190.82% | 0.02% | -95.41% | -4.09% |
| Income Tax | 0 | 95K | -28K | -4.47M | -3.08M | -44K |
| Effective Tax Rate % | 0.91% | 0.99% | 0.99% | 6.28% | 0.96% | 1% |
| Net Income | -20.73M | -17.71M | -50.87M | 5.34M | -73.35M | -61.07M |
| Net Margin % | -3.03% | -3.67% | -189.79% | 0.12% | -91.46% | -4.08% |
| Net Income Growth % | - | 0.15% | -1.87% | 1.11% | -14.73% | 0.17% |
| Net Income (Continuing) | -22.7M | -17.93M | -51.11M | 5.32M | -73.45M | -61.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 367.19K | 391K | 437K | 305K | 211K | 106K |
| EPS (Diluted) | -436.87 | -2.24 | -1.37 | 0.14 | -1.91 | -1.55 |
| EPS Growth % | - | 0.99% | 0.39% | 1.1% | -14.64% | 0.19% |
| EPS (Basic) | -436.87 | -2.24 | -1.37 | 0.14 | -1.91 | -1.55 |
| Diluted Shares Outstanding | 7.82M | 7.9M | 37.19M | 38.17M | 38.39M | 39.35M |
| Basic Shares Outstanding | 7.82M | 7.9M | 37.19M | 37.25M | 38.39M | 39.35M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 16.25M | 47.9M | 226.76M | 213.04M | 156.91M | 125.74M |
| Cash & Short-Term Investments | 11.43M | 43.27M | 214.05M | 194.38M | 142.09M | 110.66M |
| Cash Only | 11.43M | 43.27M | 214.05M | 194.38M | 142.09M | 110.66M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.91M | 518K | 11.72M | 18.05M | 7.94M | 13M |
| Days Sales Outstanding | 208.38 | 39.22 | 15.96K | 147.34 | 3.61K | 316.94 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 3.04M | -3.62M | -5.28M | 1.47M | 2.08M |
| Total Non-Current Assets | 2.79M | 2.77M | 53.95M | 57.16M | 57.6M | 34.59M |
| Property, Plant & Equipment | 2.79M | 2.77M | 9.09M | 15.71M | 19.4M | 11.76M |
| Fixed Asset Turnover | 2.45x | 1.74x | 0.03x | 2.85x | 0.04x | 1.27x |
| Goodwill | 0 | 0 | 12.63M | 12.21M | 12.21M | 0 |
| Intangible Assets | 0 | 0 | 31.43M | 28.27M | 25.11M | 21.95M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 804K | 976K | 882K | 881K |
| Total Assets | 19.04M | 50.67M | 280.71M | 270.2M | 214.51M | 160.33M |
| Asset Turnover | 0.36x | 0.10x | 0.00x | 0.17x | 0.00x | 0.09x |
| Asset Growth % | - | 1.66% | 4.54% | -0.04% | -0.21% | -0.25% |
| Total Current Liabilities | 5.75M | 7.64M | 11.16M | 12.24M | 12.6M | 15.66M |
| Accounts Payable | 3.89M | 4.67M | 2.42M | 3.75M | 1.6M | 2.47M |
| Days Payables Outstanding | 47.56 | 118.4 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 159K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 269.91K | 0 | 182K | 0 | 0 | 1000K |
| Other Current Liabilities | 373.89K | 245K | 1.42M | 1.93M | 6.01M | 1.77M |
| Current Ratio | 2.83x | 6.27x | 20.32x | 17.40x | 12.45x | 8.03x |
| Quick Ratio | 2.83x | 6.27x | 20.32x | 17.40x | 12.45x | 8.03x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.37M | 46.17M | 17M | 14.76M | 14.91M | 14.54M |
| Long-Term Debt | 0 | 44.7M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.61M | 1.47M | 6.54M | 8.34M | 11.19M | 10.09M |
| Deferred Tax Liabilities | 0 | 0 | 8.08M | 3.75M | 574K | 438K |
| Other Non-Current Liabilities | 33.76M | 0 | 2.37M | 2.68M | 3.15M | 4.01M |
| Total Liabilities | 41.12M | 53.81M | 28.15M | 27M | 27.51M | 30.19M |
| Total Debt | 1.78M | 46.36M | 7.22M | 8.77M | 12.98M | 12.01M |
| Net Debt | -9.65M | 3.1M | -206.83M | -185.61M | -129.11M | -98.66M |
| Debt / Equity | - | - | 0.03x | 0.04x | 0.07x | 0.09x |
| Debt / EBITDA | - | - | - | 31.11x | - | - |
| Net Debt / EBITDA | - | - | - | -658.20x | - | - |
| Interest Coverage | -192.53x | -5.57x | -16.95x | -212.68x | -2996.93x | -1282.45x |
| Total Equity | -22.08M | -3.15M | 252.56M | 243.2M | 187M | 130.13M |
| Equity Growth % | - | 0.86% | 81.25% | -0.04% | -0.23% | -0.3% |
| Book Value per Share | -2.82 | -0.40 | 6.79 | 6.37 | 4.87 | 3.31 |
| Total Shareholders' Equity | -22.45M | -3.54M | 252.13M | 242.9M | 186.78M | 130.03M |
| Common Stock | 330 | 0 | 1K | 1K | 1K | 1K |
| Retained Earnings | -37.89M | -57.72M | -108.58M | -103.24M | -176.59M | -237.66M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -467.36K | -1.24M | -8.49M | -33.46M | -23.32M | -25.87M |
| Minority Interest | 367.19K | 391K | 437K | 305K | 211K | 106K |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -18.76M | -11.03M | -32.58M | -14.43M | -50.92M | -28.94M |
| Operating CF Margin % | -2.74% | -2.29% | -121.58% | -0.32% | -63.5% | -1.93% |
| Operating CF Growth % | - | 0.41% | -1.95% | 0.56% | -2.53% | 0.43% |
| Net Income | -20.82M | -17.93M | -51.11M | 5.32M | -73.45M | -61.18M |
| Depreciation & Amortization | 346.86K | 208K | 602K | 4.32M | 5.43M | 5.8M |
| Stock-Based Compensation | 0 | 3.63M | 16.49M | 9.88M | 5.05M | 4.71M |
| Deferred Taxes | 0 | 0 | -119K | -4.34M | -3.08M | -44K |
| Other Non-Cash Items | -1.23M | 1.15M | 8.74M | -24.09M | 8.94M | 19.18M |
| Working Capital Changes | 2.94M | 1.92M | -7.18M | -5.52M | 6.17M | 2.6M |
| Change in Receivables | -963.16K | 774K | -3.05M | -4.67M | 5.67M | -2.35M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.98M | 586K | -3.53M | 1.14M | -3.38M | 898K |
| Cash from Investing | 1.93M | -293K | -12.91M | -5.75M | -5.41M | -892K |
| Capital Expenditures | -128.35K | -293K | -1.15M | -6.14M | -5.41M | -892K |
| CapEx % of Revenue | 0.02% | 0.06% | 4.28% | 0.14% | 6.75% | 0.06% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 388K | 0 | 0 |
| Cash from Financing | 1 | 41.44M | 222.74M | 325K | 1.87M | 2.16M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 194K | -5.27M | 0 | -163K | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -18.89M | -11.32M | -33.73M | -20.57M | -56.34M | -29.83M |
| FCF Margin % | -2.76% | -2.35% | -125.85% | -0.46% | -70.25% | -1.99% |
| FCF Growth % | - | 0.4% | -1.98% | 0.39% | -1.74% | 0.47% |
| FCF per Share | -2.42 | -1.43 | -0.91 | -0.54 | -1.47 | -0.76 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.62x | 0.64x | -2.70x | 0.69x | 0.47x |
| Interest Paid | 0 | 2K | 1.84M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 152K | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -40.79% | 2.16% | -34.1% | -38.52% |
| Return on Invested Capital (ROIC) | - | - | -148.49% | -5.87% | -109.01% | -114.09% |
| Gross Margin | -335.97% | -198.42% | 100% | 100% | 100% | 100% |
| Net Margin | -302.84% | -367.27% | -18979.48% | 11.95% | -9145.51% | -408% |
| Debt / Equity | - | - | 0.03x | 0.04x | 0.07x | 0.09x |
| Interest Coverage | -192.53x | -5.57x | -16.95x | -212.68x | -2996.93x | -1282.45x |
| FCF Conversion | 0.90x | 0.62x | 0.64x | -2.70x | 0.69x | 0.47x |
| Revenue Growth | - | -29.57% | -94.44% | 16580.22% | -98.21% | 1766.46% |
| 2023 | 2024 | |
|---|---|---|
| License | 802K | 14.97M |
| License Growth | - | 1766.46% |
Barinthus Biotherapeutics plc (BRNS) reported $15.0M in revenue for fiscal year 2024. This represents a 119% increase from $6.8M in 2019.
Barinthus Biotherapeutics plc (BRNS) grew revenue by 1766.5% over the past year. This is strong growth.
Barinthus Biotherapeutics plc (BRNS) reported a net loss of $75.9M for fiscal year 2024.
Barinthus Biotherapeutics plc (BRNS) has a return on equity (ROE) of -38.5%. Negative ROE indicates the company is unprofitable.
Barinthus Biotherapeutics plc (BRNS) had negative free cash flow of $31.0M in fiscal year 2024, likely due to heavy capital investments.